<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356472</url>
  </required_header>
  <id_info>
    <org_study_id>MRSA-VAP YANG ZT CN</org_study_id>
    <nct_id>NCT01356472</nct_id>
  </id_info>
  <brief_title>Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia</brief_title>
  <official_title>Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As previous studies showed that the synergy between linezolid and carbapenem in vitro and in
      vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and
      in combination with carbapenem against methicillin-resistant Staphylococcus aureus (MRSA) in
      ventilator-associated pneumonia (VAP) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Linezolid is the only commercially available oxazolidinone, the first new class of antibiotic
      to be developed in the last three decades. Although it is predominantly bacteriostatic,
      linezolid has good in vitro and in vivo activity against MRSA . However, several studies did
      not show that linezolid was superior to any of glycopeptides in treatment of MRSA pneumonia.
      Moreover, combination therapy against MRSA is argued when several in vitro and in vivo
      studies showed synergy between linezolid and carbapenem or fosfomycin or rifampicin, while
      vancomycin and linezolid in combination should be avoided. our study is aim to investigate
      the activity of linezolid, alone and in combination with carbapenem against
      methicillin-resistant Staphylococcus aureus (MRSA) in ventilator-associated pneumonia (VAP)
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRSA eradication</measure>
    <time_frame>7 th day</time_frame>
    <description>The investigators study the efficacy of Linezolid combined with Imipenem to treat the MRSA VAP, the investigators proposed the 7th day's MRSA eradication would be better than Linezolid alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRSA eradication</measure>
    <time_frame>14th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28th day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Methicillin-resistant Staphylococcus Aureus</condition>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <arm_group>
    <arm_group_label>Linezolid alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the control group is designed for linezolid alone treated MRSA VAP (standard treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/cilastatin</intervention_name>
    <description>the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP</description>
    <arm_group_label>Linezolid alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pneumonia, Ventilator-associated

               -  the presence of new or persistent radiographic features

               -  fever higher than 38°C

               -  leukocytosis (≥11.0 ×109/L) or neutropenia (≤3.5×109/L)

               -  purulent endotracheal

               -  increasing oxygen requirements

          -  Endotracheal aspiration culture show methicillin-resistant S. aureus positive

        Exclusion Criteria:

          -  immunocompromised patients (postorgan transplantation or human immunodeficiency
             virus-infected or neutropenic [≤1×109/L absolute neutrophils], or patients receiving
             corticosteroids &gt;20 mg/d for 6 months)

          -  colonized chronically with methicillin-resistant S. aureus

          -  pregnancy

          -  endotracheal aspiration culture showed no MRSA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Er-Zhen Chen, M.D. &amp; Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Emergency intensive care unit, Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong-Ping Qu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory intensive care unit, Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Xing Ni, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microbiology laboratory, Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhi-Tao Yang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Emergency Department, Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Tao Yang, M.D.</last_name>
    <phone>008613611965436</phone>
    <email>yangzhitao@hotmail.fr</email>
  </overall_contact>
  <reference>
    <citation>Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V, Kergueris MF, Bugnon D, Potel G, Caillon J. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Jan;49(1):45-51.</citation>
    <PMID>15616274</PMID>
  </reference>
  <reference>
    <citation>Jacqueline C, Caillon J, Grossi O, Le Mabecque V, Miegeville AF, Bugnon D, Batard E, Potel G. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006 Jul;50(7):2547-9.</citation>
    <PMID>16801442</PMID>
  </reference>
  <reference>
    <citation>Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001 Feb 1;32(3):402-12. Epub 2001 Jan 26.</citation>
    <PMID>11170948</PMID>
  </reference>
  <reference>
    <citation>Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005 Nov;56(5):923-9. Epub 2005 Sep 29.</citation>
    <PMID>16195255</PMID>
  </reference>
  <reference>
    <citation>Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002 Jun 1;34(11):1481-90. Epub 2002 May 13.</citation>
    <PMID>12015695</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>YANG Zhi-Tao</name_title>
    <organization>Emergency Department, Ruijin Hospital</organization>
  </responsible_party>
  <keyword>Methicillin-resistant Staphylococcus aureus</keyword>
  <keyword>Pneumonia, Ventilator-Associated</keyword>
  <keyword>linezolid</keyword>
  <keyword>imipenem/cilastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

